BBP

Virtus LifeSci Biotech Products ETF
--

66
*Unless otherwise stated, data provided by FactSet.

BBP Fund Description

BBP tracks an index of biotechnology companies considered to be in the "product stage" by the index provider.

BBP Factset Analytics Insight

BBP offers a different approach to biotech investing by handpicking only firms that have attained FDA approval for their leading drug. The fund is offered by BioShares alongside launched a sister fund, BBC, which targets biotech firms in the clinical trial stage. BBP is likely to tilt smaller than our neutral cap-weighted benchmark because the fund equal-weights its holdings, and it dips into micro-caps as well. Unsurprisingly, risk is elevated compared to our benchmark. BBP can be tricky to trade at any scale. Onscreen volume is thin and spreads are large, while the small-cap basket may cause some liquidity problems for larger investors. It also charges a very high expense ratio for this segment. Overall, BBP provides an alternative but pricey take on the biotech segment.

BBP MSCI ESG Analytics Insight

Virtus LifeSci Biotech Products ETF has an MSCI ESG Fund Rating of B based on a score of 2.54 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. Virtus LifeSci Biotech Products ETF ranks in the 5th percentile within its peer group and in the 8th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

BBP MSCI FaCS and Factor Box

MSCI FaCS is a standard method for evaluating and reporting the Factor characteristics of equity portfolios including ETFs. The Factor Box includes 6 Factors that MSCI has identified that historically provided a return premium. On the vertical axis, the Factor Groups, are displayed and the horizontal axis displays the Factor exposure, overweight, underweight or neutral.

BBP Charts And Performance

Price Chart ($)
Total Return Chart (%)
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
Compare
Reset
Select ETFs to compare their performance:
PERFORMANCE [as of 09/16/19] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
BBP -0.75% -2.05% 8.86% -13.10% 6.48% -- --
BBP (NAV) 1.59% 1.62% 11.03% -11.54% 5.58% -- --
Thomson Reuters US Biotechnology & Medical Research -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

BBP Summary Data

Virtus
12/17/14
Open-Ended Fund
0.79%
$26.60M
$182.93K
0.23%

BBP Portfolio Data

$14.73B
-16.34
5.76
0.20%
N/A
39

BBP Index Data

Equal
Proprietary
Thomson Reuters US Biotechnology & Medical Research

BBP Portfolio Management

0.79%
--
--
--

BBP Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

BBP Fund Structure

Open-Ended Fund
No
Yes
No Policy
N/A
N/A
High
Daily
Cboe Book Viewer
Top Of Book
Last 10 Trades
Bats BZX Real-time Quote -
Daily Spread
Premium/Discount
Volume

BBP Factset Analytics Block Liquidity

As of 09/17/19
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of BBP. BBP is rated a 4 out of 5.

BBP Tradability

4,626
$182.93K
1,870
$73.97K
0.23%
$0.09
-0.06%
1.53% / -2.39%
None
100.00%
50,000
0.04
0.03%
0.27%
0
$38.76
4

BBP Sector/Industry Breakdown


BBP
Segment Benchmark
41.92%
55.96%
38.88%
41.69%
8.69%
--
7.91%
--
2.60%
--

BBP Countries


BBP
Segment Benchmark
100.00%
100.00%

BBP Regions


BBP
Segment Benchmark
100.00%
100.00%

BBP Economic Development


BBP
Segment Benchmark
100.00%
100.00%

BBP Performance Statistics

0.90
1.12
1.22
1.03
0.57%
Thomson Reuters US Biotechnology & Medical Research

BBP MSCI ESG Ratings

B
2.54 / 10
8.30
4.60
--
29.63%
28.51

BBP Benchmark Comparison Holdings

39
140
31
30.29%

BBP Benchmark Comparison Summary


BBP
Segment Benchmark
39
140
$14.73B
$27.97B
-16.34
-135.14
5.76
4.98
0.18%
0.70%
Medium
High

BBP Benchmark Comparison Market Cap Size


BBP
Segment Benchmark
23.92%
49.65%
36.14%
32.22%
33.27%
15.58%
6.68%
2.56%